GLP-1RA

DRUG4 trials

Sponsors

Kaiser Permanente, Brigham and Women's Hospital, Ana Palanca, University of Virginia

Conditions

Cardiovascular DiseasesCardiovascular EventsEpicardial Adipose TissueHeart Failure Preserved Ejection FractionObesityRenal DiseaseType 2 DiabetesType 2 Diabetes Mellitus

Phase 4

Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

Not yet recruitingNCT07178145

University of VirginiaEpicardial Adipose Tissue, Heart Failure Preserved Ejection Fraction

Start: 2025-09-30End: 2029-12-31Target: 192Updated: 2025-09-17

Unknown Phase

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

CompletedNCT05073692

Kaiser PermanenteCardiovascular Diseases, Type 2 Diabetes Mellitus

Start: 2021-07-01End: 2025-03-12Updated: 2025-11-21

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Active, not recruitingNCT05220917

Brigham and Women's HospitalCardiovascular Events, Renal Disease, Type2 Diabetes

Start: 2021-08-01End: 2026-07-01Target: 781430Updated: 2025-12-08

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity

CompletedNCT05535322

Ana PalancaObesity, Type 2 Diabetes

Start: 2014-01-01End: 2022-09-01Updated: 2022-09-28

Related Papers

Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes

Diabetes Therapy2023-02-2735 citations